# Research Project 1

> **NIH NIH U54** · FLORIDA AGRICULTURAL AND MECHANICAL UNIV · 2021 · $290,651

## Abstract

Summary/Abstract
The principal focus of this proposal is to develop polyisoprenylated cysteinyl amide inhibitors (PCAIs) as
a novel class of targeted therapies to address the void of effective drugs for the treatment of triple
negative breast cancer (TNBC) that afflicts a significantly higher proportion of African Americans.
Hyperactivities of polyisoprenylated pathway proteins and their modulating factors are currently the
principal drivers of the most difficult-to-treat cancers such as TNBC. In fact, Cdc42 and EGFR/HER1 are
overexpressed in 95% and 91% of breast cancers, respectively. RASA1 loss-of-function mutations in
61% and 72% of breast cancers and TNBC, respectively, is functionally equivalent to Ras hyperactivity
given its role as a Ras-GTPase. Developing effective drugs for cancers with hyperactivities of Ras and
related proteins has been very challenging. Despite numerous efforts, there are no effective therapies for
cancers with these aberrations. This proposal adopts a hitherto unexplored approach to address this
problem using an entirely novel class of compounds targeting polyisoprenylated protein metabolism and
function. This is based on previous studies showing that polyisoprenylation pathway modifications are
essential for polyisoprenylated protein control on cell proliferation, differentiation, apoptosis and
cytoskeletal organization. The studies will address the hypothesis that PCAIs disrupt signaling pathways
that promote cancer cell proliferation and tumor growth as well as the cell migration and invasion that
promote metastastic TNBC. This is rationalized by the vast evidence in the scientific literature showing
that hyperactivities of monomeric G-proteins drive a large number of TNBC cases and our own
preliminary results clearly showing the effectiveness of the PCAIs to block 3D spheroid invasion,
apoptosis, angiogenesis and inhibition of TNBC xenograft tumor volume. Furthermore, our other findings
reveal that non-cytotoxic concentrations disrupt F-actin organization and lower the levels of key proteins
that mediate F-actin organization. The proposed studies are therefore aimed at broadening these studies
by (1) Synthesizing new PCAIs analogs and determining their detailed inhibitory effects against
basal and EGF- and VEGF-induced 3 D spheroid TNBC cell growth and invasion, (2) Determining
the anticancer mechanisms of PCAIs (3) Determining the in vivo effects of the PCAIs in 3D patient-
derived TNBC organoids and in TNBC xenografts. It is anticipated that upon the completion of the
studies, a clear rationale for the continuous development of this entirely new class of drugs to treat TNBC
that disproportionately affects minorities will be firmly established.

## Key facts

- **NIH application ID:** 10134817
- **Project number:** 5U54MD007582-36
- **Recipient organization:** FLORIDA AGRICULTURAL AND MECHANICAL UNIV
- **Principal Investigator:** NAZARIUS SAAH LAMANGO
- **Activity code:** U54 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $290,651
- **Award type:** 5
- **Project period:** 1997-08-01 → 2024-02-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10134817

## Citation

> US National Institutes of Health, RePORTER application 10134817, Research Project 1 (5U54MD007582-36). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10134817. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*